Nicotine withdrawal symptoms contribute to relapse in smokers, thereby prolonging the harm caused by smoking. To investigate the molecular basis for this phenomenon, we conducted a genome-wide association study of DSM-IV nicotine withdrawal in a sample of African American (AA) and European American (EA) smokers. A combined AA and EA meta-analysis (n = 8021) identified three highly correlated single nucleotide polymorphisms (SNPs) in the protocadherin (PCDH)-α, -β and -γ gene cluster on chromosome 5 that were associated with nicotine withdrawal (P o 5 × 10
INTRODUCTION
Tobacco smoking is a persistent global public health problem that is responsible for over five million deaths annually. 1, 2 Because there are clear health benefits of quitting smoking irrespective of smoking history, current age or presence of smoking-induced diseases, [1] [2] [3] efforts to promote smoking cessation are a high public health priority. More than 95% of smoking quit attempts fail within 1 year, 4 and symptoms of nicotine withdrawal (NicW) are a major precipitating factor for relapse. 5, 6 It has been argued that the severity of NicW symptoms, rather than the number of cigarettes smoked or the severity of nicotine dependence, best predicts the outcome of smoking cessation attempts. 7 Thus, understanding the genetics of NicW could help to improve tobacco smoking cessation treatment efforts and significantly reduce the harm caused by smoking.
NicW has both an affective/cognitive component (for example, irritability, frustration, anxiety, depressed mood, restlessness and difficulty concentrating) and a somatic component (for example, insomnia, decreased heart rate, increased appetite, constipation, cough and dizziness). 8 NicW symptoms are thought to be mediated by neuroadaptations that affect the function of nicotinic acetylcholine receptors, notably α2, β2, α5, α6 and β4. [9] [10] [11] For example, single-photon emission computed tomography studies indicate that β2*-nicotinic acetylcholine receptor availability increases during early abstinence and remains at elevated levels for~1 month before returning to baseline. 12, 13 Changes in the firing of dopaminergic neurons in the ventral tegmental area that reduce the amount of dopamine released into the nucleus accumbens may also contribute to the development of symptoms of NicW, 14, 15 as well as symptoms of withdrawal from opioids, cocaine and alcohol. 16 Human functional magnetic resonance imaging neuroimaging studies have provided additional insight into the neuroadaptations that may be responsible for NicW, and several studies have shown that NicW disrupts resting state functional connectivity in the brain. 17 These cessation-induced disruptions in functional connectivity are associated with cognitive impairments and craving to smoke. 18 Although genetic variation influences the development of NicW, few risk genes have been identified. [19] [20] [21] [22] The identification of risk genes could provide insight into the molecular mechanism of NicW in humans. We conducted a genome-wide association study (GWAS) of DSM-IV NicW in a combined sample of 8021 European American (EA) and African American (AA) tobacco smokers. The sample was recruited for studies on the genetics of cocaine, opioid and alcohol dependence (Yale-Penn study), Addiction: Genetics and Environment (SAGE), which are available to researchers through dbGAP (Database of Genotypes and Phenotypes). [26] [27] [28] We previously published a GWAS of Fagerstrom Test for Nicotine Dependence score that was based partially on this dataset. 29 On the basis of the GWAS findings, we investigated the association of an identified NicW risk allele in the protocadherin (PCDH)-α, -β and -γ gene cluster with characteristics of NicW in an independent intravenous (IV) nicotine infusion study. The IV nicotine infusion study included tobacco smokers who had completed a~10-h period of smoking abstinence. We also characterized the effects of the NicW-associated risk allele on gene regulatory mechanisms and PCDH-α, -β and -γ gene expression using publically available transcriptomic and epigenomic data from postmortem human brain.
MATERIALS AND METHODS Subjects
The EA and AA participants in the NicW GWAS are described in Table 1 . The Yale-Penn-1 and Yale-Penn-2 subjects were recruited at multiple eastern US sites for genetic studies of drug and alcohol dependence, as described elsewhere. [23] [24] [25] These subjects were phenotyped using the polydiagnostic Semi-Structured Assessment for Drug Dependence and Alcoholism (SSADDA). 30 Yale-Penn study participants provided written informed consent prior to their participation and the institutional review board at each participating site approved the studies. The National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism issued Certificates of Confidentiality to protect Yale-Penn study participants. The GWAS also included data from the SAGE, 26 obtained via the database of Genotypes and Phenotypes (accession: phs000092.v1.p1). The SAGE dataset includes subjects from COGA (the Collaborative Study on the Genetics of Alcoholism), 28 FSCD (the Family Study of Cocaine Dependence) 27 and COGEND (the Collaborative Genetic Study of Nicotine Dependence). 26 Only subjects who smoked at least 100 cigarettes in their lifetime were included in the GWAS.
The NicW diagnosis was based on DSM-IV, which requires that four NicW symptoms be experienced within the first 24 h after either quitting or smoking less than usual, or smoking (or using other nicotine-containing products) to avoid problems caused by quitting or smoking less than usual. The NicW symptoms included: (i) Were you irritable, angry or frustrated? (ii) Were you nervous or anxious? (iii) Were you restless? (iv) Did you have trouble concentrating? (v) Did your heart slow down? (vi) Did you feel down or depressed? (vii) Did you have such a strong desire for cigarettes that you couldn't think of anything else? (viii) Did your appetite increase or did you gain weight? (ix) Did you have trouble sleeping? Table 1 shows the number of subjects and NicW rates for each study group and demographic and smoking-related characteristics.
The laboratory study, which was conducted independently from the GWAS, included 179 non-treatment-seeking EA (50%) and AA (50%) smokers recruited from the New Haven, Connecticut area. Seventy-three percent of subjects were male and the mean age was 36.2 (s.d. = 8.9) years. Some subjects from this sample have been included in previous studies, including genetic studies related to smoking and nicotine. [31] [32] [33] [34] All laboratory subjects smoked 410 cigarettes per day for the past year and had expired carbon monoxide levels of ⩾ 10 ppm at the initial screening. On the basis of a structured interview (Structured Clinical Interview for DSM-IV), 35 the subjects were free of major medical problems and current psychiatric disorders, including dependence on alcohol or drugs (other than nicotine). Plasma nicotine, cotinine and 3'-hydroxycotinine concentrations were measured at baseline (prior to nicotine infusion) using high-performance liquid chromatography interfaced with tandem mass spectrometry, as previously described. 31, 36 Baseline Minnesota Nicotine Withdrawal Scale (MNWS) 37 and Brief Questionnaire of Smoking Urges (BQSU) 38 were completed after IV lines were established. After baseline assessments, subjects were administered IV doses of saline, followed in a uniform order by escalating doses of nicotine (0.5 mg per 70 kg of body weight and 1 mg per 70 kg of body weight). Each infusion lasted 30 s and was separated from the preceding one by 30 min. The first dose of nicotine, 0.5 mg per 70 kg of body weight, is approximately equal to the dose of nicotine delivered by smoking one-half of a cigarette, while the second dose of nicotine, 1.0 mg per 70 kg of body weight, is approximately equal to the dose of nicotine delivered by smoking one cigarette. 39 Subjects repeated the MNWS and BQSU 20 min after the final infusion of nicotine. One hundred seventy-nine subjects completed the MNWS and 177 subjects completed the BQSU. The distribution of MNWS and BQSU outcomes is shown in Supplementary Figure S2 . DSM-IV NicW was not measured in the laboratory subjects. All laboratory study subjects provided written informed consent prior to participation, and were paid for their participation. Yale University and the VA Connecticut Healthcare System institutional review boards approved the laboratory study.
Genotyping and genotype imputation
The array-genotyped single nucleotide polymorphism (SNP) data were acquired with the following Illumina (San Diego, CA, USA) arrays: YalePenn-1 by the HumanOmni1-Quad v1.0; Yale-Penn-2 by the HumanCore Exome BeadChip; and SAGE by the Human 1M. IMPUTEv2 software 40 was used to impute additional SNPs for each array. The 1000 Genomes June 2011 (http://www.1000genomes.org/) release was used as the reference for imputation. The 1000 Genomes reference included phased haplotypes for 1094 individuals of diverse ancestries, including samples of European descent, Asian descent, African descent and an ad-mixed American sample. 41 SNPs with imputed information scores o0.80 and minor allele frequencies o2.5 percent (for both imputed and directly genotyped SNPs) were excluded from the GWAS analysis. To evaluate our GWAS finding of Abbreviations: FTND, Fagerstrom Test for Nicotine Dependence; ND, DSM-IV nicotine-dependent; SAGE, Study of Addiction: Genetics and Environment. a DSM-IV nicotine withdrawal symptom; *Estimated based on non-missing age of use data, which was 98% of the total data. association between NicW and PCDH-α, -β and -γ gene cluster variation, the laboratory subjects were genotyped for rs31746 with a 2 μl TaqMan allelic discrimination assay (Applied Biosystems, Foster City, CA, USA). We considered rs31746 to be the 'best' SNP to select for follow-up studies in the laboratory sample because in contrast to the other two SNPs, rs31746 was directly genotyped by all arrays and it was positioned in a regulatory element. The majority of laboratory subjects (n = 124) were assigned to either EA or AA ancestry groups on the basis of a previously described ancestry informative genetic marker method. 32, 42 Subjects not assigned by a genetic ancestry were assigned on the basis of their self-reported ancestry. Four subjects with a genetic assignment that was discordant with the self-report were re-assigned to the ancestry group defined by the genetic markers.
Analysis
Quality control procedures were performed with PLINK 43 and EIGENSOFT v4.2.
44,45 using array-based genotype calls. EA and AA subjects were analyzed separately. One subject was retained from each group of related subjects (identity-by-descent 40.25). Subjects were excluded from the present study if they were ever more than six standard deviations from the mean of principal component 1, 2 or 3 during five iterations of principal component analysis in EIGENSOFT v4.2. 44, 45 Association testing was performed with PLINK. 43 The SNP was coded as the allele dosage, and age, sex and the first 10 principal components (to control for population stratification) were included as covariates. We observed acceptable genomic inflation factor (λ) values for our analyses that included 10 principal components and no additional steps were taken to include or exclude covariates from the model. The results from each array were combined by meta-analysis. SNPs were excluded from the meta-analyses if they were not present (either directly genotyped or well-imputed) in all studies. There were 7 445 053 SNPs for the AA sample, 5 675 219 SNPs for the EA sample and 4 795 232 SNPs for the EA+AA sample. Regional associations were evaluated with plots generated using LocusZoom (http:// locuszoom.sph.umich.edu/locuszoom). 46 For laboratory participants, BQSU and MNWS effects were analyzed with linear mixed models using JMP Pro (v10.0.0) software (SAS Institute, Cary, NC, USA). The following independent variables were included in the models as fixed effects: rs31746 genotype (with number of risk allele copies coded additively as 0, 1 and 2), sex, population (EA or AA), time point (pre-or post-nicotine) and the interaction of time point with rs31746 genotype. A random effect was included to account for correlations between the repeated measures from each subject. We performed additional analyses to control for the potential confounding effects of differences in baseline smoking behavior, evaluating the fold-change in BQSU with models that included the following independent variables: sex, race, baseline nicotine plasma concentration, baseline cotinine plasma concentration and baseline nicotine metabolite ratio.
SNP functional annotation and characterization
A literature search led us to previous work identifying DNase I hypersensitivity (HS) sites and CTCF-binding sites important in regulating the expression of genes in the PCDH gene cluster. [47] [48] [49] The positions of NicW-associated SNPs relative to these regulatory regions were examined using the following UCSC Genome Browser tracks: 'DNaseI HS Density Signal from ENCODE/Duke' track for ventromedial prefrontal cortex and fibroblast tissue, and 'Transcription Factor ChIP-seq (161 factors) from ENCODE' track for CCCTC-binding factor (CTCF).
50-52 HS5-1 sites were mapped to the genome using primers that had been previously used to generate electrophoretic mobility shift assay probes for HS5-1a and HS5-1b. 47 UCSC Genome Browser 51 screenshots containing the indicated track data were used to illustrate the relative position of the SNPs and regulatory elements. The P-values for the association of rs31746 with PCDH-α, -β and -γ gene cluster mRNA expression were extracted from BrainCloud (http:// braincloud.jhmi.edu/; dbGaP Study Accession: phs000417.v2.p1). 53 BrainCloud includes data from human prefrontal cortex tissue and an association with gene expression in other brain regions was not tested. Fifty-five different PCDH-α, -β and -γ gene mRNAs were targeted by 63 probes. All gene names and corresponding expression P-values are shown in Supplementary Table S3 .
RESULTS

GWAS of NicW symptoms: rs31746 associated with NicW across populations
The demographic characteristics of GWAS subjects are shown in Table 1 . There was little evidence of systemic P-value inflation (genomic inflation factor λ o 1.029) for the EA, AA or EA+AA GWAS meta-analyses (Figure 1a and Supplementary Figure S1 ). There were no NicW associations (P 45 × 10 − 8 ) observed in the metaanalyzed EA or AA samples. In the meta-analyzed EA+AA sample, three closely mapped SNPs (rs246592, rs31746, rs31743) in an intergenic position within the PCDH-α, -β and -γ gene cluster on chromosome 5 ( Figure 1b) were associated with NicW after a genome-wide test correction (P meta o5 × 10 − 8 ). No heterogeneity was detected in the meta-analysis (Cochran's Q, P40.5, I 2 = 0). The statistical strength of the association was nearly indistinguishable among the three SNPs (P = 2.3 × 10 − 8 -4.8 × 10 − 8 ) and, as indicated by the 1000 Genome Project data, 41 the pairwise correlation between all SNPs was high in populations of European (r 2 = 1, D' = 1) and African (r 2 40.66, D'40.98) ancestry. Rs31746 was directly genotyped by all arrays used in the study. The effect of rs31746, as indicated by the magnitude and direction of the odds ratio, was consistent across the six studies that were included in the meta-analysis (Figure 2) . The rs31746*A allele (EA frequency = 68%; AA frequency = 47%) was associated with elevated risk for NicW (odds ratio meta = 1.21 (95% confidence interval 1.13-1.30); P = 3.67 × 10 − 8 ). The association of rs31746 to each individual DSM-IV NicW criterion for Yale-Penn 1 and Yale-Penn 2 subjects is shown in Supplementary Table S2 . On the basis of the EA+AA meta-analysis, the strongest associations were observed for 'Did you feel down or depressed?' (P meta = 5 × 10 − 4 ), 'Were you irritable, angry or frustrated?' (P meta = 5 × 10 − 4 ) and 'Were you restless?' (P meta = 1 × 10 − 3 ). The individual DSM NicW criterion data were unavailable for SAGE subjects.
Rs31746 is associated with smoking urges in smokers following overnight abstinence and intravenous nicotine infusion To extend our GWAS findings and gain insight into the potential behavioral basis for the association of PCDH-α, -β and -γ gene SNPs with NicW, we investigated one of the genome-wide significant SNPs, rs31746, in relation to withdrawal characteristics in a sample of current smokers who participated in an IV nicotine infusion laboratory study (n = 179). Because this SNP was directly genotyped by all GWAS arrays, we considered it the strongest association signal and the best SNP in the region to select for follow-up analysis. The laboratory procedure was initiated after the subjects completed an overnight (~10 h) period of smoking abstinence. This time period is sufficient for the development of withdrawal symptoms in dependent smokers. 54, 55 Following the IV nicotine infusion session, features of NicW were lower than at the pre-infusion baseline (main effect of time point: BQSU: F (1,175) = 105.89, P o 0.001; MNWS: F (1,177) = 63.01, P o0.001). The change in BQSU, but not MNWS, in response to the nicotine infusion session differed by rs31746 genotype (genotype by time point interaction: BQSU: F (1,175) = 5.37, P = 0.022) (Figure 3a ). There was no significant main effect of rs31746 genotype on BQSU or MNWS. The interactive effect of genotype was similar for BQSU Factor 1, the urge to smoke for reward (F (1,175) = 4.40, P = 0.037), and BQSU Factor 2, the urge to smoke to relieve negative affect (F (1,175) = 4.68, P = 0.032). The withdrawal risk allele, rs31746*A, was associated with a greater percent reduction in the urge to smoking following the nicotine infusion session. The average percent reduction in total BQSU score by rs31746 genotype was 32% for AA, 19% for AG and 11% for GG (Figure 3b) . Genotype was associated with change in BQSU score after adjusting for baseline plasma cotinine and nicotine levels, and nicotine metabolite ratio (main effect of rs31746, P o0.02). The effect was also consistent among EA and AA subjects when the two groups were analyzed separately (EA genotype by time point interaction for BQSU: F (1,85) = 2.87, P = 0.094; AA genotype by time point interaction for BQSU: F (1,88) = 2.88, P = 0.093). The average percent reduction in total BQSU score by rs31746 genotype was similar for EA subjects (30% for AA, 19% for AG and 16% for GG) and AA subjects (34% for AA, 19% for AG and 10% for GG).
Rs31746 maps to a long-range neuron-specific enhancer element and is associated with gene expression in human brain To gain insight into the potential molecular mechanisms linking PCDH-α, -β and -γ gene cluster SNPs to NicW risk, we surveyed the three NicW-associated SNPs and their flanking sequences for evidence of potential regulatory effects. As shown in Figure 4a , rs31746 mapped to a region with marked DNAse1 HS, whereas rs31743 and rs246592 did not. The DNAse1 HS site presented in Figure 4a contains HS5-1a and HS5-1b, components of a previously characterized neuron-specific enhancer element (HS5-1) that regulates the expression of PCDH-α, -β and -γ genes. 48, 56 Rs31746 mapped to within a 113 base-pair element that corresponds to HS5-1a. 47 CCCTC-binding factor (CTCF), which is required for the regulatory function of HS5-1, binds to HS5-1a (Figure 4a ). On the basis of the position of rs31746 within this regulatory element, we hypothesized that rs31746 could affect PCDH-α, -β and -γ gene expression. To test this, we used BrainCloud human prefrontal cortex gene expression data to query the association of rs31746 with the expression of 55 different PCDH-α, -β and -γ gene cluster mRNAs that were targeted by 63 probes. We observed a robust association between rs31746 and PCDHβ8 mRNA expression (Figure 4b) . The withdrawal risk 140,300,000 140,300,000 140,400,000 140,400,000 140,500,000 140,500,000 140,600,000 140,600,000 140,700,000 140,700,000 140,800,000 140,800,000 PCDHA1  PCDHA1  PCDHA1  PCDHA2  PCDHA2  PCDHA2  PCDHA3  PCDHA3  PCDHA4  PCDHA4  PCDHA4  PCDHA5  PCDHA5  PCDHA5  PCDHA6  PCDHA6  PCDHA6  PCDHA7  PCDHA7   PCDHA8   PCDHA8  PCDHA9  PCDHA9   PCDHA10   PCDHA10  PCDHA10   AX746964   PCDHA11   PCDHA11   PCDHA12  PCDHA12   PCDHA13   PCDHA13  PCDHA13   PCDHAC1   PCDHAC1  PCDHAC2   PCDHAC2   PCDHB1  PCDHB2  PCDHB2  BC016751  PCDHB3   PCDHB4   PCDHB5   PCDHB6  PCDHB17  PCDHB7   PCDHB8   PCDHB16   PCDHB9  PCDHB10   PCDHB11   PCDHB12   PCDHB12   PCDHB13   PCDHB14   PCDHB18   PCDHB19P   PCDHB15  SLC25A2  TAF7  PCDHGA1  PCDHGA1  PCDHGA2  PCDHGA2  PCDHGA3  PCDHGA3  PCDHGB1  PCDHGB1  PCDHGA4  PCDHGA4   PCDHGB2   PCDHGB2  PCDHGA5  PCDHGA5  PCDHGB3  PCDHGB3  PCDHGA6  PCDHGA6   PCDHGA7   PCDHGA7  PCDHGA8  PCDHGB4   PCDHGA8   PCDHGB5   PCDHGB5   PCDHGA9   PCDHGA9  PCDHGB6  PCDHGB6  PCDHGA10  PCDHGA10   PCDHGB7   PCDHGB7   PCDHGA11  PCDHGA11  PCDHGA11   PCDHGB8P   PCDHGA12   PCDHGA12   PCDHGC3   PCDHGC3   PCDHGC3   PCDHGC4   PCDHGC4   PCDHGC5   PCDHGC5   rs246592  rs31746  rs31743  HS5- allele, rs31746*A, was associated with lower PCDHβ8 mRNA expression (P = 5.32 × 10 − 6 ).
DISCUSSION
NicW is common among tobacco smokers and its symptoms contribute to smoking relapse following quit attempts. Using GWAS, we identified three highly correlated SNPs in the PCDH-α, -β and -γ gene cluster that were associated with DSM-IV NicW. Subsequently, we evaluated the influence of one of these SNPs, rs31746, on smoking withdrawal behavior in an independent sample of current tobacco smokers who had abstained from smoking for~10 h. Following IV nicotine infusion, the NicW risk allele was associated with a greater reduction in the urge to smoke, a clinically relevant characteristic of NicW. 6 That is, individuals with the NicW risk allele experienced greater alleviation of their withdrawal symptoms in a laboratory setting following nicotine infusion. Rs31746 is located within a previously characterized PCDH-α, -β and -γ gene cluster neuron-specific enhancer element, HS5-1. Using publically available data, we observed a robust association between rs31746 and PCDHβ8 mRNA expression in postmortem human prefrontal cortex tissue. Our results indicate that NicW risk is influenced by regulatory variation in the PCDH-α, -β and -γ gene cluster.
Our initial association finding emerged from a GWAS of six separately analyzed samples derived from three independent cohorts containing nearly 4400 EA subjects and more than 3600 AA subjects. The results of the nicotine infusion laboratory study, which used a different study design from the GWAS, supported the GWAS finding by showing an association of the rs31746*A allele with a greater change in the urge to smoke, a clinically important characteristic of NicW. This critical insight suggests one potential mechanism, regulation of smoking urges and craving, by which rs31746 might influence NicW risk. However, the laboratory study subjects had a~10-h period of smoking abstinence and there was no association of rs31746 to NicW characteristics at the smoking abstinence baseline prior to nicotine infusion. Evaluating genotype effects in subjects after a longer period of abstinence might also be informative given prior work suggesting that some withdrawal symptoms peak 2-3 days post cessation. 57 The limited abstinence period may be why we observed effects for QSU but not MNWS. Withdrawal symptoms and urges are similar constructs that follow different time courses during abstinence, and some research suggests that BQSU may have greater sensitivity to early abstinence (24 h) compared with the MNWS. [58] [59] [60] Real-time behavioral assessments of NicW in abstinent smokers over an extended period could provide important additional insight into the role of rs31746 in NicW. Alternatively, the size of the laboratory sample may have limited the statistical power to detect some effects during early abstinence.
The NicW-associated SNPs mapped to the PCDH-α, -β and -γ gene cluster. Genes expressed from this~800-kilobase region on human chromosome 5 encode structurally similar transmembrane proteins that are enriched at the synapses of neurons. 61 The expression of PCDH-α, -β and -γ genes in the nervous system is tightly controlled. 62, 63 The specific position of rs31746 within the gene cluster is noteworthy; it maps to HS5-1, a previously characterized long-range, neuron-specific enhancer element. [47] [48] [49] The critical function of this regulatory element is supported by several studies, including data compiled by ENCODE on DNAse hypersensitivity and transcription factor binding. Rs31746 is within HS5-1a, a component of HS5-1 that interacts directly with CTCF. 47 HS5-1 recruits CTCF and additional proteins that control the chromatin structure of the PCDH-α, -β and -γ gene region. Through protein partners, HS5-1 and other cis-regulatory elements in the region direct long-range DNA looping and interactions that facilitate the expression of specific PCDH-α, -β and -γ gene mRNAs via alternative promoter usage. [47] [48] [49] 56, 64 Targeted deletion of HS5-1 in mice reduced the expression of PCDHβ8 mRNA, which we observed to be associated with the rs31746*A risk allele. 56 The position of rs31746 in a previously characterized and important regulatory element identifies it as a strong candidate for follow-up studies on molecular mechanisms linking the PCDH-α, -β and -γ genes to NicW risk.
PCDH-α, -β and -γ genes are important for many neuronal processes, [65] [66] [67] but there have been few behavioral studies of the function of specific PCDH-α, -β and -γ genes. Mice genetically engineered to express low levels of PCDH-α had abnormal fearrelated contextual learning and working memory. 68 Using RNAseq to investigate changes in the mouse nucleus accumbens, Eipper-Mains et al. 69 observed dynamic alterations in PCDH-α, -β and -γ gene mRNA expression in response to cocaine and cocaine withdrawal. McGowan et al. 70 observed that the PCDH-α, -β and -γ gene cluster was differentially regulated by epigenetic mechanisms in the brains of adult rats following a low versus high earlylife maternal care paradigm. This well-established early-life stress paradigm induces later-life differences in hypothalamic-pituitaryadrenal axis function. 70, 71 Interestingly. Suderman et al. 72 found that syntenic regions in the human PCDH-α, -β and -γ gene cluster were differentially regulated in subjects who had experienced severe abuse during childhood, suggesting a potentially conserved mechanism for responding to early-life stressors. These findings are concordant with the important role of stress regulation and stress response pathways in NicW and smoking relapse. 34, [73] [74] [75] [76] [77] [78] Combined, these studies indicate that PCDH-α, -β and -γ mRNA expression is altered in the mammalian brain in response to stimuli. Alterations that affect brain functional connectivity are thought to be associated with many neuropsychiatric disorders, including nicotine addiction. 79 Future research is warranted to examine the specific effects of PCDH-α, -β and -γ genes on brain functional connectivity.
Some study limitations should be noted. A genome-wide significant effect was only observed with a meta-analysis of six studies (n = 8021), which may reflect limited power. The top GWAS SNP remained significant (P o 5 × 10 − 8 ) after correction for genomic inflation (λ = 1.025); however, a spurious finding due to underlying ancestry differences within samples or due to chance cannot be completely excluded. The observed effects related to NicW in an independent laboratory sample support the validity of the GWAS finding. In addition, the GWAS sample included subjects recruited for genetic studies of alcohol, cocaine and opioid use disorder, while the laboratory study recruited just for tobacco use disorder. Rs31746 was associated only with nicotine dependence (P meta = 5 × 10 − 4 ) in the combined GWAS sample and not alcohol, cocaine or opioid dependence (P meta 40.05), but the high prevalence of these co-occurring disorders in the GWAS sample could limit the generalizability of the results. Although prior work has linked NicW symptoms to smoking relapse following a quit attempt, 6 ,7,80 we could not evaluate a potential moderating effect of the NicW risk variant on relapse rate after smoking cessation. Additional studies will be required to determine how the NicW risk SNPs influence withdrawal symptoms and relapse in a treatment context.
In summary, using GWAS we identify a regulatory SNP in the PCDH-α, -β and -γ gene cluster that was associated with NicW and smoking urges. Additional studies of these genes in response to stress, nicotine, and NicW are warranted. Understanding and potentially alleviating NicW symptoms could facilitate smoking cessation, thereby significantly reducing the harm associated with smoking.
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